Summary: Researchers have identified a compound that can stabilize a protein implicated in ALS and SMA.
Harvard Stem Cell Institute (HSCI) researchers have identified a compound that helps protect the cells destroyed by spinal muscular atrophy (SMA), the most frequent fatal genetic disease in children under 2 years of age.
SMA is a neurodegenerative disease targeting motor neurons, the long nerve cells that relay messages from the brain to the muscles and that are, consequently, responsible for bodily movements, including walking, swallowing, and even breathing. Patients with milder forms of SMA experience muscle wasting that may confine them to a wheelchair, while the more severe forms cause paralysis and death before the second birthday.
About one in 50 people are genetic carriers of the disease.
Because of a dysfunctional gene, many motor neurons in SMA patients are unable to produce adequate amounts of a protein called survival of motor neuron (SMN). The deficiency causes cellular stress and eventually cell death. Rather than fixing the gene, which has been the strategy of many labs looking to develop SMA therapies, the Harvard team has identified a compound that helps stabilize the SMN protein both in human neurons in a dish and in mouse models.
The findings were published in the journal Cell Reports.
“This discovery opens up new lines of drug interrogation,” said Lee Rubin, HSCI principal faculty member and the senior author on the study. Rubin’s lab, which operates out of in Harvard’s Department of Stem Cell and Regenerative Biology, uses induced pluripotent stem cells (iPS cells) to make human models of neurological diseases.
In 2015, Rubin made a variety of neuronal types from the iPS cells of SMA patients in order to determine why motor neurons in particular were targeted, and found they experienced a fatal stress response similar to motor neurons affected by amyotrophic lateral sclerosis (ALS), the late-onset neurodegenerative disease more commonly known as Lou Gehrig’s disease.
Additionally, some SMA-affected motor neurons were dying before others, though all of the neurons had the same genetic mutations and were experiencing the same stressful environment.
“Clearly, some motor neurons were surviving, so the next question was whether this is random or if there is a molecular explanation,” Rubin said.
Early on in their most recent study, the researchers found that within a single petri dish of motor neurons derived from an SMA patient, some produced up to four times as much SMN protein as their neighbors. Over time, those motor neurons with higher levels of SMN were more likely to survive after exposure to toxic environments and stressors.
When the team analyzed motor neurons derived from ALS patients, they found similar results: Motor neurons with higher levels of SMN were likelier to survive than those with lower levels.
“The surprise was when we looked in a control culture and also saw differences between the individual neurons,” Rubin said.
“It is clear that the SMN protein is necessary for all motor neuron survival, not just motor neurons targeted by ALS or SMA,” said Natalia Rodríguez-Muela, a postdoctoral fellow in Rubin’s lab and co-first author on the paper. The results suggest that if the team could increase the amount of SMN protein in any single motor neuron, they would be able to rescue the cell.
During a cell’s life span, proteins are constantly being made and degraded, made and degraded again. To interrupt the process of breaking down the SMN protein, the researchers looked at a family of proteins called Cullins, which act as a part of the cell machinery that regulates protein degradation.
In 2011, the Rubin lab had determined that an enzyme called GSK3b helps control SMN stability. Nearly all proteins degraded by GSK3b are flagged for degradation by a pathway that involves a specific member of the Cullin family. Rubin said the researchers hypothesized that if they could block that Cullin-mediated process, the SMN proteins would not be flagged for degradation and would remain stable longer.
The researchers, led by co-first author Nadia Litterman, then dosed human and murine motor neurons with a compound known to block the specific Cullin and found that exposure to the compound made SMN proteins more stable and more abundant. As a consequence, the compound promoted survival of all motor neurons, both in human cells in the dish and in mouse models.
Additionally, mice with SMA, even the more severe forms of the disease, had some of their symptoms improve after exposure to the compound.
“This process points to an unexplored therapeutic direction that could benefit patients of not one, but two separate diseases,” Rubin said.
About this neurology research article
Harvard’s Office of Technology Development has filed a patent application on the approach.
Funding: This work was supported by the SMA Foundation, National Institute of Neurological Disorders and Stroke grant P01 NS066888, National Institutes of Health grants NS045523 and NS075672, Massachusetts Spinal Cord Injury Research Trust, and the Harvard Stem Cell Institute.
Source: Hannah L. Robbins – Harvard Image Source: NeuroscienceNews.com image is credited to Natalia Rodriguez-Muela. Original Research: Full open access research for “Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease” by Natalia Rodriguez-Muela, Nadia K. Litterman, Erika M. Norabuena, Jesse L. Mull, Maria José Galazo, Chicheng Sun, Shi-Yan Ng, Nina R. Makhortova, Andrew White, Maureen M. Lynes, Wendy K. Chung, Lance S. Davidow, Jeffrey D. Macklis, and Lee L. Rubin in Cell Reports. Published online March 14 2017 doi:10.1016/j.celrep.2017.01.035
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]Harvard “Common Drug Could Help Treat ALS and SMA.” NeuroscienceNews. NeuroscienceNews, 17 April 2017. <https://neurosciencenews.com/sma-als-neuropharmacology-6422/>.[/cbtab][cbtab title=”APA”]Harvard (2017, April 17). Common Drug Could Help Treat ALS and SMA. NeuroscienceNew. Retrieved April 17, 2017 from https://neurosciencenews.com/sma-als-neuropharmacology-6422/[/cbtab][cbtab title=”Chicago”]Harvard “Common Drug Could Help Treat ALS and SMA.” https://neurosciencenews.com/sma-als-neuropharmacology-6422/ (accessed April 17, 2017).[/cbtab][/cbtabs]
Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease
Highlights •MN cultures from SMA or ALS patients or controls contain cells with different SMN levels •In these cultures, high SMN MNs survive better than MNs harboring low SMN levels •An Nedd8-activating enzyme inhibitor increases SMN and survival of ALS and SMA MNs •The effect of drugs that correct SMN2 splicing is limited to SMA and not ALS
Summary The mechanism underlying selective motor neuron (MN) death remains an essential question in the MN disease field. The MN disease spinal muscular atrophy (SMA) is attributable to reduced levels of the ubiquitous protein SMN. Here, we report that SMN levels are widely variable in MNs within a single genetic background and that this heterogeneity is seen not only in SMA MNs but also in MNs derived from controls and amyotrophic lateral sclerosis (ALS) patients. Furthermore, cells with low SMN are more susceptible to cell death. These findings raise the important clinical implication that some SMN-elevating therapeutics might be effective in MN diseases besides SMA. Supporting this, we found that increasing SMN across all MN populations using an Nedd8-activating enzyme inhibitor promotes survival in both SMA and ALS-derived MNs. Altogether, our work demonstrates that examination of human neurons at the single-cell level can reveal alternative strategies to be explored in the treatment of degenerative diseases.
“Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease” by Natalia Rodriguez-Muela, Nadia K. Litterman, Erika M. Norabuena, Jesse L. Mull, Maria José Galazo, Chicheng Sun, Shi-Yan Ng, Nina R. Makhortova, Andrew White, Maureen M. Lynes, Wendy K. Chung, Lance S. Davidow, Jeffrey D. Macklis, and Lee L. Rubin in Cell Reports. Published online March 14 2017 doi:10.1016/j.celrep.2017.01.035